The concentrations inducing growth inhibitoryeffects in melanoma cells seem to be different depending on the PPARγ agonist used and the melanoma cell employed.In particular, it remains to be further explored whether activation of PPARγ itself or PPARγ-independent effects of PPARγ agonists contribute to the inhibition ofmelanoma cell growth. This evidence concerns the gene PPARG and melanoma.